Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
01.11.24
12:48 Uhr
0,087 Euro
-0,009
-9,70 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart

Aktuelle News zur KAROLINSKA DEVELOPMENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.10.Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine31STOCKHOLM, SWEDEN, October 21, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines, has presented positive clinical safety and immunogenicity...
► Artikel lesen
15.10.Notice of Extraordinary General Meeting in Karolinska Development AB (publ)1
23.09.Karolinska Development AB (publ): Karolinska Development divests its holding in the Danish dermatology company Henlez1
17.09.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01100STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed the AC01-FE study in the US and also completed...
► Artikel lesen
17.09.Karolinska Development AB (publ): Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease110STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented positive top-line results from a clinical...
► Artikel lesen
30.08.Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG0052
30.08.Karolinska Development AB (publ): Interim Report - January-June 202486STOCKHOLM - 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The full report is available on the Company's website. "The successes...
► Artikel lesen
16.07.Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator2
10.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone1
12.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection113STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead...
► Artikel lesen
28.05.Karolinska Development AB (publ): Karolinska Development invests in BOOST Pharma, expanding its portfolio1
16.05.Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 20241
08.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC1
26.04.Karolinska Development AB (publ): Interim Report - January-March 2024109STOCKHOLM - 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. "2024...
► Artikel lesen
14.03.Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million255STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company's IND application...
► Artikel lesen
16.02.Karolinska Development AB (publ): Year-end Report - January-December 2023219STOCKHOLM - 16 February 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report - January-December 2023. The full report is available on the Company's website....
► Artikel lesen
09.01.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product267STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line...
► Artikel lesen
06.12.23Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates241STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market...
► Artikel lesen
04.12.23Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo's drug candidate PN6047 in a NIDA funded collaboration183STOCKHOLM, SWEDEN, December 4, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo's drug candidate PN6047 will be evaluated as a potential...
► Artikel lesen
28.11.23Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis194STOCKHOLM, SWEDEN - November 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented positive results from a study...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1